Home > Research > Publications & Outputs > Neuroprotective effects of geniposide on Alzhei...
View graph of relations

Neuroprotective effects of geniposide on Alzheimer's disease pathology

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Neuroprotective effects of geniposide on Alzheimer's disease pathology. / Liu, WeiZhen; Li, Guanglai; Holscher, Christian et al.
In: Reviews in the Neurosciences, Vol. 26, No. 4, 08.2015, p. 371-383.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Liu, W, Li, G, Holscher, C & Li, L 2015, 'Neuroprotective effects of geniposide on Alzheimer's disease pathology', Reviews in the Neurosciences, vol. 26, no. 4, pp. 371-383. https://doi.org/10.1515/revneuro-2015-0005

APA

Vancouver

Liu W, Li G, Holscher C, Li L. Neuroprotective effects of geniposide on Alzheimer's disease pathology. Reviews in the Neurosciences. 2015 Aug;26(4):371-383. Epub 2015 Apr 16. doi: 10.1515/revneuro-2015-0005

Author

Liu, WeiZhen ; Li, Guanglai ; Holscher, Christian et al. / Neuroprotective effects of geniposide on Alzheimer's disease pathology. In: Reviews in the Neurosciences. 2015 ; Vol. 26, No. 4. pp. 371-383.

Bibtex

@article{4a3aa7f038b049c583b0e138c9a168b7,
title = "Neuroprotective effects of geniposide on Alzheimer's disease pathology",
abstract = "A growing body of evidence has linked two of the most common aged-related diseases: type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD). It has led to the notion that drugs developed for the treatment of T2DM may be beneficial in modifying the pathophysiology of AD. As a receptor agonist of glucagon-like peptide-1 (GLP-1R), which is a newer drug class to treat T2DM, geniposide shows clear effects in inhibiting pathological processes underlying AD, such as promoting neurite outgrowth. In the present article, we review the possible molecular mechanisms of geniposide to protect the brain from pathologic damages underlying AD: reducing amyloid plaques, inhibiting τ phosphorylation, preventing memory impairment and loss of synapses, reducing oxidative stress and the chronic inflammatory response, and promoting neurite outgrowth via the GLP-1R signaling pathway. In summary, the Chinese herb geniposide shows great promise as a novel treatment for AD.",
keywords = "Alzheimer{\textquoteright}s disease, amyloid-β, geniposide, glucagon-like peptide receptor, neurofibrillary tangles, neuroprotection , oxidative stress, τ protein, type 2 diabetes mellitus",
author = "WeiZhen Liu and Guanglai Li and Christian Holscher and Lin Li",
note = "Date of Acceptance: 25/02/2015",
year = "2015",
month = aug,
doi = "10.1515/revneuro-2015-0005",
language = "English",
volume = "26",
pages = "371--383",
journal = "Reviews in the Neurosciences",
issn = "0334-1763",
publisher = "WALTER DE GRUYTER GMBH",
number = "4",

}

RIS

TY - JOUR

T1 - Neuroprotective effects of geniposide on Alzheimer's disease pathology

AU - Liu, WeiZhen

AU - Li, Guanglai

AU - Holscher, Christian

AU - Li, Lin

N1 - Date of Acceptance: 25/02/2015

PY - 2015/8

Y1 - 2015/8

N2 - A growing body of evidence has linked two of the most common aged-related diseases: type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD). It has led to the notion that drugs developed for the treatment of T2DM may be beneficial in modifying the pathophysiology of AD. As a receptor agonist of glucagon-like peptide-1 (GLP-1R), which is a newer drug class to treat T2DM, geniposide shows clear effects in inhibiting pathological processes underlying AD, such as promoting neurite outgrowth. In the present article, we review the possible molecular mechanisms of geniposide to protect the brain from pathologic damages underlying AD: reducing amyloid plaques, inhibiting τ phosphorylation, preventing memory impairment and loss of synapses, reducing oxidative stress and the chronic inflammatory response, and promoting neurite outgrowth via the GLP-1R signaling pathway. In summary, the Chinese herb geniposide shows great promise as a novel treatment for AD.

AB - A growing body of evidence has linked two of the most common aged-related diseases: type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD). It has led to the notion that drugs developed for the treatment of T2DM may be beneficial in modifying the pathophysiology of AD. As a receptor agonist of glucagon-like peptide-1 (GLP-1R), which is a newer drug class to treat T2DM, geniposide shows clear effects in inhibiting pathological processes underlying AD, such as promoting neurite outgrowth. In the present article, we review the possible molecular mechanisms of geniposide to protect the brain from pathologic damages underlying AD: reducing amyloid plaques, inhibiting τ phosphorylation, preventing memory impairment and loss of synapses, reducing oxidative stress and the chronic inflammatory response, and promoting neurite outgrowth via the GLP-1R signaling pathway. In summary, the Chinese herb geniposide shows great promise as a novel treatment for AD.

KW - Alzheimer’s disease

KW - amyloid-β

KW - geniposide

KW - glucagon-like peptide receptor

KW - neurofibrillary tangles

KW - neuroprotection

KW - oxidative stress

KW - τ protein

KW - type 2 diabetes mellitus

U2 - 10.1515/revneuro-2015-0005

DO - 10.1515/revneuro-2015-0005

M3 - Journal article

C2 - 25879319

VL - 26

SP - 371

EP - 383

JO - Reviews in the Neurosciences

JF - Reviews in the Neurosciences

SN - 0334-1763

IS - 4

ER -